New stock questions plague HHS nominee Tom Price as confirmation vote nears
WASHINGTON President Trump's choice to be the top U.S. health official bought and sold health care company stocks often enough as a member of Congress to warrant probes by both federal securities regulators and the House ethics committee, former government ethics lawyers say.
A USA TODAY analysis of stock trade reports by Rep. Tom Price, R-Ga., also shows he often misstated the timing of stock purchases or failed to report them altogether.
These include disclosures related to his much-publicized investment in the Australian biotech company Innate Immunotherapeutics, which gave him preferential treatment for a private stock offering he learned of through another member of Congress who is the company's biggest shareholder.
Price also invested in more health care companies that could benefit from legislation he introduced than previously reported.
When asked about Price's stock trades, the Department of Health and Human Services released an unsigned statement that said Price's legislative activity on behalf of the medical equipment industry, which dates back about 20 years, illustrated his long-held concerns with the CMS' competitive bidding process.
http://www.usatoday.com/story/news/politics/2017/02/08/new-stock-questions-plague-hhs-nominee-tom-price/97555796/